论文部分内容阅读
目的通过南京市胸科医院门急诊抗结核药的应用分析,促进临床合理用药。方法对南京市胸科医院2014年至2016年门诊急诊抗结核药23个品种、用量、销售金额、用药频度等进行回顾性分析、统计。结果(1)南京市胸科医院门急诊抗结核药销售金额逐年增加。各年度一线抗结核药销售金额占销售总额的20%~30%,二线抗结核药占销售总额的70%~80%。注射剂型金额构成比不到10%,以口服剂型为主。(2)DDDs排名,各年度前3名均属于一线抗结核用药,分别是乙胺丁醇、异烟肼和利福平。第4名和第5名属于二线抗结核药。(3)DDDc排名前3名属于新型抗结核药。结论一线抗结核药仍占主导地位,用药合理。二线抗结核药疗效显著,受临床青睐。新型抗结核药市场前景良好,适用于耐多药和广泛耐药结核病。通过血药浓度检测及基因多态性研究,调整抗结核药给药剂量,实现抗结核病个体化治疗,减少耐药率、复发率,降低不良反应,减轻患者经济负担,是一种新探索。
Objective Through the application analysis of outpatient and emergency department of Nanjing Chest Hospital, to promote clinical rational use of drugs. Methods Retrospective analysis and statistics of 23 varieties, dosage, sales amount and frequency of anti-TB drugs in outpatient emergency department of Nanjing Chest Hospital from 2014 to 2016 were performed. Results (1) The sales volume of outpatient and emergency department antituberculosis drugs in Nanjing Chest Hospital increased year by year. The annual sales of first-line anti-TB drugs account for 20% to 30% of the total sales, while second-line anti-TB drugs account for 70% to 80% of total sales. Injections form the amount of less than 10%, mainly to oral dosage forms. (2) DDDs rankings, the first three of each year are first-line anti-TB drugs, namely ethambutol, isoniazid and rifampicin. 4th and 5th are second-line anti-TB drugs. (3) DDDc ranked the top three new antituberculosis drugs. Conclusion The first-line anti-TB drugs still dominate and the medication is reasonable. Second-line anti-TB drugs significant effect, favored by the clinic. The new antituberculosis drugs have a good market prospect and are suitable for multidrug-resistant and widely drug-resistant tuberculosis. It is a new exploration to detect the dose of anti-tuberculosis drug, to achieve the individualized treatment of anti-tuberculosis, to reduce the rate of drug resistance and relapse, to reduce the adverse reaction and to reduce the economic burden of patients through the study of blood concentration and gene polymorphism.